Patents by Inventor Kenzo Muramoto
Kenzo Muramoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110105427Abstract: The present invention provides compounds having formula (I): wherein R1, R2, R3 and n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally.Type: ApplicationFiled: November 2, 2010Publication date: May 5, 2011Inventors: Jane Daun, Heather A. Davis, Bruce DeCosta, Fabian Gusovsky, Ieharu Hishinuma, Yimin Jiang, Toshihiko Kaneko, Kouichi Kikuchi, Seiichi Kobayashi, André Lescarbeau, Xiang-Yi Li, Kenzo Muramoto, Norihito Ohi, Marc Pesant, Boris M. Seletsky, Motohiro Soejima, Mark Spyvee, Lynda Tremblay, Ye Yao, Hiromitsu Yokohama, Yan (Janet) Zhao, Wanjun Zheng
-
Patent number: 7915306Abstract: The present invention provides compositions comprising compounds having formula (I): and additionally provides methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R1-R11, X, Y, Z, and n are as defined herein. In certain embodiments, the compositions are for systemic (e.g., oral) administration. In certain embodiments, methods for the treatment of various disorders including inflammatory or autoimmune disorders comprise systemically (e.g., orally) administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I).Type: GrantFiled: September 9, 2003Date of Patent: March 29, 2011Assignee: Eisai Co., Ltd.Inventors: Kenichi Chiba, Hong Du, Yoshihito Eguchi, Masanori Fujita, Masaki Goto, Fabian Gusovsky, Jean-Christophe Harmange, Atsushi Inoue, Megumi Kawada, Takatoshi Kawai, Yoshiyuki Kawakami, Akifumi Kimura, Makoto Kotake, Yoshikazu Kuboi, Tomohiro Matsushima, Yoshiharu Mizui, Kenzo Muramoto, Hideki Sakurai, Yong-Chun Shen, Hiroshi Shirota, Mark Spyvee, Isao Tanaka, John (Yuan) Wang, Ray Wood, Satoshi Yamamoto, Naoki Yoneda
-
Patent number: 7868002Abstract: As discussed above, there remains a need for the development of novel therapeutic agents useful for treating inflammatory or autoimmune and proliferative diseases. The present invention provides novel compounds of general formula (I), and pharmaceutical compositions thereof, as described generally and in classes and subclasses herein, as well as methods of making and using such compounds.Type: GrantFiled: September 28, 2007Date of Patent: January 11, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Jane Daun, Heather A. Davis, Bruce DeCosta, Fabian Gusovsky, Ieharu Hishinuma, Yimin Jiang, Toshihiko Kaneko, Kouichi Kikuchi, Seiichi Kobayashi, André Lescarbeau, Xiang-Yi Li, Kenzo Muramoto, Norihito Ohi, Marc Pesant, Boris M. Seletsky, Motohiro Soejima, Mark Spyvee, Lynda Tremblay, Ye Yao, Hiromitsu Yokohama, Yan (Janet) Zhao, Wanjun Zheng
-
Publication number: 20100305098Abstract: A method of treating a disorder such as rheumatoid arthritis or multiple sclerosis in a subject is carried out by administering to the subject a composition comprising a modulator compound of Th1 differentiation or Th17 expansion.Type: ApplicationFiled: November 13, 2008Publication date: December 2, 2010Inventors: Qian Chen, Jesse Cheng-Lin Chow, Fabian Gusovsky, Marc Lamphier, Matthew Faust Mackey, Kenzo Muramoto, Shawn Schiller, Christine J. Shaffer, Mark Spyvee
-
Patent number: 7799827Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R1-R11, X, Y, Z, and n are as defined herein.Type: GrantFiled: March 7, 2003Date of Patent: September 21, 2010Assignee: Eisai Co., Ltd.Inventors: Roch Boivin, Kenichi Chiba, Jesse Chow, Hong Du, Yoshihito Eguchi, Masanori Fujita, Masaki Goto, Fabian Gusovsky, Jean-Christophe Harmange, Atsushi Inoue, Yimin Jiang, Megumi Kawada, Takatoshi Kawai, Yoshiyuki Kawakami, Akifumi Kimura, Makoto Kotake, Yoshikazu Kuboi, Charles-André Lemelin, Xiang-Yi Li, Tomohiro Matsushima, Yoshiharu Mizui, Kenzo Muramoto, Hideki Sakurai, Yong-Chun Shen, Hiroshi Shirota, Mark Spyvee, Isao Tanaka, John (Yuan) Wang, Satoshi Yamamoto, Naoki Yoneda
-
Publication number: 20080248502Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies.Type: ApplicationFiled: April 28, 2005Publication date: October 9, 2008Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Keiko Yamaguchi, Toshio Imai, Kenzo Muramoto
-
Patent number: 7390490Abstract: There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there can be provided an antibody drug for suppressing chemotaxis and cytotoxic activity of killer lymphocytes by suppressing an interaction between CX3CR1 and fractalkine.Type: GrantFiled: September 13, 2005Date of Patent: June 24, 2008Assignee: Eisai Co., Ltd.Inventors: Toshio Imai, Miyuki Nishimura, Kenzo Muramoto, Yoshikazu Kuboi
-
Publication number: 20080103137Abstract: As discussed above, there remains a need for the development of novel therapeutic agents useful for treating inflammatory or autoimmune and proliferative diseases.Type: ApplicationFiled: September 28, 2007Publication date: May 1, 2008Inventors: Jane Daun, Heather Davis, Bruce DeCosta, Fabian Gusovsky, Ieharu Hishinuma, Yimin Jiang, Toshihiko Kaneko, Kouichi Kikuchi, Seiichi Kobayashi, Andre Lescarbeau, Xiang-Yi Li, Kenzo Muramoto, Norihito Ohi, Marc Pesant, Boris Seletsky, Motohiro Soejima, Mark Spyvee, Lynda Tremblay, Ye Yao, Hiromitsu Yokohama, Yan (Janet) Zhao, Wanjun Zheng
-
Patent number: 7314936Abstract: The present invention provides compounds having formula (I), wherein R1, R2, R3 and n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generallyType: GrantFiled: January 7, 2003Date of Patent: January 1, 2008Assignee: Eisai Co., Ltd.Inventors: Jane Daun, Heather A. Davis, Bruce DeCosta, Fabian Gusovsky, Ieharu Hishinuma, Yimin Jiang, Toshihiko Kaneko, Kouichi Kikuchi, Seiichi Kobayashi, André Lescarbeau, Xiang-Yi Li, Kenzo Muramoto, Norihito Ohi, Marc Pesant, Boris M. Seletsky, Motohiro Soejima, Mark Spyvee, Lynda Tremblay, Ye Yao, Hiromitsu Yokohama, Yan (Janet) Zhao, Wanjun Zheng
-
Publication number: 20070219178Abstract: The preventive or therapeutic agents of the present invention for multiple sclerosis comprise compounds represented by the following formula (I), or salts or hydrates thereof, [wherein, T1, X, Z1, Z2, and R1 have the same meaning as T1, X, Z1, Z2, and R1 in this application].Type: ApplicationFiled: October 7, 2004Publication date: September 20, 2007Applicant: Eisai Co., Ltd.Inventor: Kenzo Muramoto
-
Publication number: 20060247448Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R1-R11, X, Y, Z, and n are as defined herein.Type: ApplicationFiled: March 7, 2003Publication date: November 2, 2006Applicant: Eisai Co., Ltd.Inventors: Roch Boivin, Kenichi Chiba, Jesse Chow, Hong Du, Yoshihito Eguchi, Masanori Fujita, Masaki Goto, Fabian Gusovsky, Jean-Christophe Harmanage, Atsushi Inoue, Yimin Jiang, Megumi Kawada, Takatoshi Kawai, Yoshiyuki Kawakami, Akifumi Kimura, Makoto Kotake, Yoshikazu Kuboi, Charles-Andre Lemelin, Xiang-Yi Li, Tomohiro Matsushima, Yoshiharu Mizui, Kenzo Muramoto, Hideki Sakurai, Yong-Chun Shen, Hiroshi Shirota, Mark Spyvee, Isao Tanaka, John Wang, Satoshi Yamamoto, Naoki Yoneda
-
Publication number: 20050124649Abstract: The present invention provides compounds having formula (I), wherein R1, R2, R3 and n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally.Type: ApplicationFiled: January 7, 2003Publication date: June 9, 2005Applicant: EISAI CO., LTDInventors: Jane Daun, Heather Davis, Bruce DeAcosta, Fabian Gusovsky, Ieharu Hishinuma, Yimin Jiang, Toshihiko Kaneko, Kouichi Kikuchi, Seiichi Kobayashi, Andre Lescarbeau, Xiang-Yi Li, Kenzo Muramoto, Norihito Ohi, Marc Pesant, Boris Seletsky, Mark Spyvee, Lynda Tremblay, Ye Yao, Hiromitsu Yokohama, Yan (Janet) Zhao, Wanjun Zheng
-
Publication number: 20040224936Abstract: The present invention provides compositions comprising compounds having formula (I): 1Type: ApplicationFiled: September 9, 2003Publication date: November 11, 2004Inventors: Kenichi Chiba, Hong Du, Yoshihito Eguchi, Masanori Fujita, Masaki Goto, Fabian Gusovsky, Jean-Christophe Harmange, Atsushi Inoue, Megumi Kawada, Takatoshi Kawai, Yoshiyuki Kawakami, Akifumi Kimura, Makoto Kotake, Yoshikazu Kuboi, Tomohiro Matsushima, Yoshiharu Mizui, Kenzo Muramoto, Hideki Sakurai, Yong-Chun Shen, Hiroshi Shirota, Mark Spyvee, Isao Tanaka, John (Yuan) Wang, Ray Wood, Satoshi Yamamoto, Naoki Yoneda
-
Publication number: 20040092737Abstract: Benzopiperidine derivatives represented by formula (I), salts thereof or hydrates thereof, processes for producing the same and drugs comprising the same: 1Type: ApplicationFiled: September 20, 2002Publication date: May 13, 2004Applicant: Eisai Co., Ltd.Inventors: Toshihiko Kaneko, Richard Clark, Norihito Ohi, Fumihiro Ozaki, Tetsuya Kawahara, Atsushi Kamada, Kazuo Okano, Hiromitsu Yokohama, Kenzo Muramoto, Tohru Arai, Masayoshi Ohkuro, Osamu Takenaka, Jiro Sonoda
-
Patent number: 6518423Abstract: Benzopiperidine derivatives represented by formula (I), salts thereof or hydrates thereof, processes for producing the same and drugs comprising the same: wherein the variables are as described in the specification. These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and rejection reaction accompanying organ transplantation.Type: GrantFiled: April 5, 1999Date of Patent: February 11, 2003Assignee: Eisai Co., Ltd.Inventors: Toshihiko Kaneko, Richard Clark, Norihito Ohi, Fumihiro Ozaki, Tetsuya Kawahara, Atsushi Kamada, Kazuo Okano, Hiromitsu Yokohama, Kenzo Muramoto, Tohru Arai, Masayoshi Ohkuro, Osamu Takenaka, Jiro Sonoda
-
Publication number: 20020192212Abstract: There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there can be provided an antibody drug for suppressing chemotaxis and cytotoxic activity of killer lymphocytes by suppressing an interaction between CX3CR1 and fractalkine.Type: ApplicationFiled: September 25, 2001Publication date: December 19, 2002Inventors: Toshio Imai, Miyuki Nishimura, Kenzo Muramoto, Yoshikazu Kuboi
-
Patent number: 5789446Abstract: To provide a treating or ameliorating agent for joint diseases accompanied with arthritis, preferably, a rheumatoid arthritis or ameliorating agent, which exerts excellent pharmaceutical effects. The active ingredient is a quinone derivative represented by the following general formula (I) or pharmacologically acceptable salts thereof: ##STR1## wherein n is 0 or an integer of 1 to 12 and R is a methyl or methoxy group.Type: GrantFiled: June 17, 1997Date of Patent: August 4, 1998Assignee: Eisai Co., Ltd.Inventors: Akiyoshi Uchiyama, Kenzo Muramoto, Kenichi Chiba, Takashi Yamanaka, Isao Yamatsu
-
Patent number: 5482937Abstract: A triazolo-1,4-di-azepine compound of the below given formula and a pharmacologically acceptable salt thereof are useful in the pharmaceutical field, especially in treating allergic diseases. ##STR1## in which R.sup.1 and R.sup.2 are hydrogen or an alkyl, R.sup.3 is hydrogen or a halogen, R.sup.4 is hydrogen or an alkyl, X is --OCO--, and Y is a cycloalkyl, a cycloalkylalkyl, an alkynyl or others.Type: GrantFiled: October 6, 1994Date of Patent: January 9, 1996Assignee: Eisai Co., Ltd.Inventors: Kazuo Okano, Shuhei Miyazawa, Richard S. J. Clark, Shinya Abe, Tetsuya Kawahara, Naoyuki Shimomura, Osamu Asano, Hiroyuki Yoshimura, Mitsuaki Miyamoto, Yoshimori Sakuma, Kenzo Muramoto, Hiroshi Obaishi, Koukichi Harada, Hajime Tsunoda, Satoshi Katayama, Kouji Yamada, Shigeru Souda, Yoshimasa Machida, Kouichi Katayama, Isao Yamatsu
-
Patent number: 5468740Abstract: A triazolo-1,4-di-azepine compound of the below given formula and a pharmacologically acceptable salt thereof are disclosed and useful in the pharmaceutical field, especially to allergic diseases. ##STR1## in which R.sup.1 and R.sup.2 are hydrogen or an alkyl, R.sup.3 is hydrogen or a halogen, R.sup.4 is hydrogen or an alkyl, X is --OCO--, --NHCO--, --CO-- or others and Y is a cycloalkyl, a cycloalkylalkyl, an alkynyl or others.Type: GrantFiled: February 10, 1995Date of Patent: November 21, 1995Assignee: Eisai Co., Ltd.Inventors: Kazuo Okano, Shuhei Miyazawa, Richard S. J. Clark, Shinya Abe, Tetsuya Kawahara, Naoyuki Shimomura, Osamu Asano, Hiroyuki Yoshimura, Mitsuaki Miyamoto, Yoshimori Sakuma, Kenzo Muramoto, Hiroshi Obaishi, Koukichi Harada, Hajime Tsunoda, Satoshi Katayama, Kouji Yamada, Shigeru Souda, Yoshimasa Machida, Kouichi Katayama, Isao Yamatsu
-
Patent number: 5438045Abstract: A triazolo-1,4-di-azepine compound of the below given formula and a pharmacologically acceptable salt thereof are disclosed and useful in the pharmaceutical field, especially to allergic diseases. ##STR1## in which R1 and R2 are hydrogen or an alkyl, R3 is hydrogen or a halogen, R4 is hydrogen or an alkyl, X is --OOO--, --NHCO--, --CO-- or others and Y is a cycloalkyl, a cycloalkylalkyl, an alkynyl or others.Type: GrantFiled: April 27, 1993Date of Patent: August 1, 1995Assignee: Eisai Co., Ltd.Inventors: Kazuo Okano, Shuhei Miyazawa, Richard S. J. Clark, Shinya Abe, Tetsuya Kawahara, Naoyuki Shimomura, Osamu Asano, Hiroyuki Yoshimura, Mitsuaki Miyamoto, Yoshimori Sakuma, Kenzo Muramoto, Hiroshi Obaishi, Koukichi Harada, Hajime Tsunoda, Satoshi Katayama, Kouji Yamada, Shigeru Souda, Yoshimasa Machida, Kouichi Katayama, Isao Yamatsu